دورية أكاديمية

Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial

التفاصيل البيبلوغرافية
العنوان: Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial
المؤلفون: Véron, Marie, Chevret, Sylvie, Grob, Jean-Jacques, Beylot-Barry, Marie, Saiag, Philippe, Fléchon, Aude, You, Benoit, Maubec, Eve, Jouary, Thomas, Toulemonde, Elise, Jamme, Philippe, Gambotti, Laëtitia, Lamrani-Ghaouti, Assia, Dupuy, Alain, Lebbe, Céleste, Seguin, Nicole Basset, Houede, Nadine, Leccia, Marie-Thérèse, Le Du, Fanny, de Pontville, Michel, Gaudy-Marquestre, Caroline, Guillot, Bernard, Simon, Clotilde, Marabelle, Aurélien, Mortier, Laurent
المصدر: In European Journal of Cancer December 2022 177:103-111
قاعدة البيانات: ScienceDirect
الوصف
تدمد:09598049
DOI:10.1016/j.ejca.2022.09.013